SVRA News and Press, Savara Inc. From 11/09/23

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Savara Inc. (SVRA) is expected to report $-0.07 for Q3 2023

Savara Inc. (NASDAQ: SVRA) is the focus of IBN's latest stock spotlight. The company's shares have moved 5.92% on the day to $3.67. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-...

Savara Inc. (NASDAQ: SVRA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.68% on the day to $3.33. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-...

Savara Inc. (NASDAQ: SVRA) is the focus of IBN's latest stock spotlight. The company's shares have moved 2.67% on the day to $3.27. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-...

Savara Inc. (NASDAQ: SVRA) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.14% on the day to $3.67. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte...

2023-10-05 17:23:44 ET Gainers: nCino ( NASDAQ: NCNO ) +8% . TPI Composites ( TPIC ) +6% . SCYNEXIS ( SCYX ) +5% . Sutro Biopharma ( STRO ) +5% . Black Diamond Therapeutics ( BDTX ) +4% . Losers: SomaLogic ( SLGC ...

Savara Inc. (NASDAQ: SVRA) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.49% on the day to $3.75. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-...

2023-09-13 09:34:50 ET Summary Savara focuses on rare respiratory diseases, with lead product molgramostim in Phase 3 for autoimmune Pulmonary Alveolar Proteinosis (aPAP). Financially stable with $185.2M in liquidity, but increased R&D expenses signal a risky, all-in approach ...

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 25 th Annual Global Investment Conference on September 12, 2023 at 3:30pm ET/12:30pm PT. A live webcast o...